Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albicidin is a natural hybrid polyketide-peptide antibiotic and phytotoxin produced by the plant pathogen Xanthomonas albilineans. It exhibits potent bactericidal activity at nanomolar concentrations against a broad spectrum of Gram-positive and Gram-negative pathogens, including fluoroquinolone-resistant strains. Albicidin acts as a DNA topoisomerase inhibitor by targeting bacterial DNA gyrase. It employs a dual mechanism of action where it binds to the gyrase dimer interface and intercalates between cleaved DNA strands, preventing DNA religation and trapping the enzyme in a cleaved complex. This unique mechanism of action makes it a promising lead compound for the development of novel antibiotics to combat multidrug-resistant bacterial infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on albicidin.